Please login to the form below

Not currently logged in
Email:
Password:

EU approval for Gilenya

Novartis' oral multiple sclerosis drug Gilenya has been approved as the first treatment of its kind for use in the European Union

Novartis' oral multiple sclerosis (MS) drug Gilenya (fingolimod) has been approved as the first treatment of its kind for use in the European Union (EU).

The drug is approved for use in patients with highly active relapsing-remitting multiple sclerosis (RRMS) who have already undergone treatment with beta interferon, or have a rapidly evolving severe form of the condition.

The announcement follows the US Food and Drug Administration's (FDA) decision to approve Gilenya for use in the US after trials showed it reduced the frequency of relapse and reduced the risk of disease progression.

It has also been approved in other regions including Switzerland and Australia.

The EU approval was preceded by a positive opinion of Gilenya from the Committee for Medicinal Products for Human Use (CHMP), an expert committee of the European Medicines Agency (EMA).

Gilenya has fared better than other oral MS treatments, including Merck Serono's cladribine. Despite being approved in Russia under the trade name Movectro, it was recently denied US approval and was given a negative opinion by CHMP.

21st March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Difference Collective

Welcome to the Difference Collective – a healthcare communications team of 80+ talented experts who Deliver Differently. We’re purpose-built around...

Latest intelligence

Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...
How scientific storytelling can help Pharma cut through the noise
Rather than being afraid of storytelling, pharmaceutical firms should be embracing it. Because what scientific storytelling allows us to do is to communicate quickly and efficiently. It provides a shortcut...